CL2015002469A1 - Anticuerpos dirigidos contra il-33 y sus usos - Google Patents

Anticuerpos dirigidos contra il-33 y sus usos

Info

Publication number
CL2015002469A1
CL2015002469A1 CL2015002469A CL2015002469A CL2015002469A1 CL 2015002469 A1 CL2015002469 A1 CL 2015002469A1 CL 2015002469 A CL2015002469 A CL 2015002469A CL 2015002469 A CL2015002469 A CL 2015002469A CL 2015002469 A1 CL2015002469 A1 CL 2015002469A1
Authority
CL
Chile
Prior art keywords
antibodies
signaling
diseases
join
interaction
Prior art date
Application number
CL2015002469A
Other languages
English (en)
Inventor
Andrew J Murphy
Nicholas Papadopoulos
Jaime M Orengo
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2015002469A1 publication Critical patent/CL2015002469A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESCNTE INVENCIÓN PROPORCIONA ANTICUERPOS QUE SE UNEN A INTERLEUQUINA-33 (IL.-33) Y MÉTODOS PARA USAR LOS MISMOS. LA INVENCIÓN INCLUVE ANTICUERPOS QUE INHIBEN O ATENUAN LA SEÑALIZACION MEDIADA POR IL-33. LOS ANTICUERPOS DE LA INVENCION PUEDEN FUNCIONAR PARA BLOQUEAR LA INTERACCION ENTRE IL. -33 '' ST2 ALTERNATIVAMENTE. DETERMNINADOS ANTICUERPOS DE LA INVENCION INHIBEN O ATENUAN IA SEÑALIZACION MEDIADA PR II .-33 SIN BLOQUEAR LA INTERACCION DE IL, -33/ST2. DE ACUERDO CON DETERMINADAS REALIZACIONES DE LA INVENCION, LOS ANTICUERPOS SON ANTICUERPOS COMPLETAMENTE HUMANOS QUE SE UNEN A LA IL-33 HUMANA CON ELEVADA AFINIDAD. LOS ANTICUERPOS DE LA INVENCION SON UTILES PARAEL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS ASOCIADOS CON LA SEÑALIZACIÓN DE IL-33 Y/O LA EXPRESION CELULAR DE IL-33. TALES COMO ENFERMEDADES INFLAMATORIAS, O ENFERMEDADES ALÉRGICAS.
CL2015002469A 2013-03-13 2015-09-04 Anticuerpos dirigidos contra il-33 y sus usos CL2015002469A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361778687P 2013-03-13 2013-03-13
US201361819018P 2013-05-03 2013-05-03

Publications (1)

Publication Number Publication Date
CL2015002469A1 true CL2015002469A1 (es) 2016-06-10

Family

ID=50678269

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015002469A CL2015002469A1 (es) 2013-03-13 2015-09-04 Anticuerpos dirigidos contra il-33 y sus usos
CL2018000101A CL2018000101A1 (es) 2013-03-13 2018-01-12 Anticuerpos dirigidos contra il-33 y sus usos (divisional de la solicitud 201502469)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2018000101A CL2018000101A1 (es) 2013-03-13 2018-01-12 Anticuerpos dirigidos contra il-33 y sus usos (divisional de la solicitud 201502469)

Country Status (29)

Country Link
US (6) US9453072B2 (es)
EP (3) EP2970460B1 (es)
JP (2) JP6479755B2 (es)
KR (1) KR102103159B1 (es)
CN (1) CN105051063B (es)
AU (1) AU2014248839B2 (es)
CA (1) CA2902172C (es)
CL (2) CL2015002469A1 (es)
DK (2) DK3683235T3 (es)
EA (1) EA031745B1 (es)
ES (2) ES2804592T3 (es)
FI (1) FI3683235T3 (es)
HR (2) HRP20200846T1 (es)
HU (2) HUE067119T2 (es)
IL (2) IL240354A0 (es)
JO (1) JO3532B1 (es)
LT (2) LT2970460T (es)
MX (2) MX377712B (es)
MY (1) MY174740A (es)
PH (1) PH12015501656A1 (es)
PL (2) PL2970460T3 (es)
PT (2) PT2970460T (es)
RS (2) RS60503B1 (es)
SG (1) SG11201505745WA (es)
SI (2) SI3683235T1 (es)
TW (1) TWI633119B (es)
UY (1) UY35417A (es)
WO (1) WO2014164959A2 (es)
ZA (1) ZA201505376B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11738081B2 (en) 2015-03-31 2023-08-29 Medimmune Limited Polynucleotides encoding IL33 antibodies and methods of using the same

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
BR112013032630B1 (pt) 2011-06-30 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Polipeptídeo heterodimerizado compreendendo região fc de igg
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
SG11201402750SA (en) 2011-11-30 2014-10-30 Chugai Pharmaceutical Co Ltd Drug containing carrier into cell for forming immune complex
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
SI2888281T1 (sl) 2012-08-21 2019-03-29 Sanofi Biotechnology Postopki zdravljenja ali preventive astme z administracijo antagonista IL-4R
AU2013306700B2 (en) 2012-08-24 2019-05-02 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc region variant
KR102249779B1 (ko) 2012-12-27 2021-05-07 추가이 세이야쿠 가부시키가이샤 헤테로이량화 폴리펩티드
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
JP6404314B2 (ja) 2013-03-15 2018-10-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−３３拮抗薬とその使用法
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
EP3783017A1 (en) 2013-04-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha Fc region variant
WO2015099175A1 (ja) 2013-12-26 2015-07-02 田辺三菱製薬株式会社 ヒト抗ｉｌ－３３中和モノクローナル抗体
ES2866935T3 (es) * 2014-01-10 2021-10-20 Anaptysbio Inc Anticuerpos dirigidos contra interleucina-33 (IL-33)
WO2015164354A1 (en) 2014-04-21 2015-10-29 The Childen's Hospital Of Philadelphia Compositions and methods for treating cytokine-related disorders
NO2785538T3 (es) 2014-05-07 2018-08-04
SG11201702544WA (en) 2014-09-29 2017-04-27 Univ Duke Bispecific molecules comprising an hiv-1 envelope targeting arm
US11708608B2 (en) * 2014-11-10 2023-07-25 Genentech, Inc. Therapeutic and diagnostic methods for IL-33-mediated disorders
AU2015346460A1 (en) * 2014-11-10 2017-03-23 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
AU2015365168B2 (en) 2014-12-19 2021-08-05 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
EP3253778A1 (en) 2015-02-05 2017-12-13 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
US10500273B2 (en) 2015-03-02 2019-12-10 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an IL-33 antagonist
CA2981957C (en) * 2015-04-06 2021-10-12 Meso Scale Technologies, Llc. High throughput system for performing assays using electrochemiluminescence including a consumable shaking apparatus
TW202440904A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（二）
HK1259386A1 (zh) * 2015-10-06 2019-11-29 Regeneron Pharmaceuticals, Inc. 与白介素-33 (il-33)介导的疾病有关的生物标志物及其用途
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
MX2018008732A (es) * 2016-01-14 2018-12-06 Anaptysbio Inc Inhibicion de la reaccion alergica usando un inhibidor de il-33.
MA44723A (fr) 2016-04-18 2019-02-27 Celldex Therapeutics Inc Anticorps agonistes se liant au cd40 humain et leurs utilisations
MA45294A (fr) * 2016-04-22 2019-02-27 Medimmune Llc Plasticité fonctionnelle d'ilc2, immunité et copd
BR112018071276A2 (pt) * 2016-04-27 2019-02-12 Pfizer Inc. anticorpos anti-il-33, composições, métodos e usos dos mesmos
PT3448391T (pt) 2016-04-27 2024-06-26 Abbvie Mfg Management Unlimited Company Métodos de tratamento de doenças nas quais a atividade de il-13 é prejudicial, utilizando anticorpos anti-il-13
KR20250008966A (ko) 2016-08-05 2025-01-16 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
EA201990912A1 (ru) * 2016-10-13 2019-10-31 Анти-lag-3 антитела и их композиции
JOP20190093A1 (ar) * 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
TWI784988B (zh) * 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
MX2019009485A (es) 2017-02-10 2019-11-05 Genentech Inc Anticuerpos contra triptasa, composiciones de estos y usos de estos.
CN108456251A (zh) * 2017-02-21 2018-08-28 上海君实生物医药科技股份有限公司 抗pd-l1抗体及其应用
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
CN110431240A (zh) * 2017-04-13 2019-11-08 雷杰纳荣制药公司 在编码il33和il1rl1的基因中具有风险等位基因的患者的炎症性肺部疾病的治疗和抑制
CN110997725B (zh) 2017-06-12 2024-08-09 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
US20190010531A1 (en) 2017-07-06 2019-01-10 Regeneron Pharmaceuticals, Inc. Cell culture process for making a glycoprotein
TWI825025B (zh) 2017-08-31 2023-12-11 日商田邊三菱製藥股份有限公司 包含il-33拮抗劑的子宮內膜異位症治療劑
WO2019098212A1 (en) 2017-11-14 2019-05-23 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
CA3084059A1 (en) 2017-12-22 2019-06-27 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
CN111655722A (zh) 2018-01-31 2020-09-11 瑞泽恩制药公司 用于表征药物产品杂质的系统和方法
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
SG11202007564VA (en) 2018-02-09 2020-09-29 Genentech Inc Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
JP2021514609A (ja) 2018-02-28 2021-06-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ウイルス混入物質を同定するためのシステムおよび方法
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
FI3768709T3 (fi) 2018-03-19 2024-02-01 Regeneron Pharma Mikrosirukapillaarielektroforeesianalyysejä ja -reagensseja
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
IL307286A (en) * 2018-04-11 2023-11-01 Regeneron Pharma Methods and preparations for quantification of IL-33
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
PE20210343A1 (es) 2018-08-10 2021-02-23 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
SG11202011969WA (en) 2018-08-30 2020-12-30 Regeneron Pharma Methods for characterizing protein complexes
JP2022517720A (ja) 2019-01-16 2022-03-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ジスルフィド結合を特徴付けるための方法
TW202519263A (zh) 2019-03-21 2025-05-16 美商再生元醫藥公司 含有抗il-33抗體之穩定調配物
MX2021013427A (es) * 2019-05-01 2022-01-31 Sanofi Biotechnology Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33.
KR20220007586A (ko) 2019-05-13 2022-01-18 리제너론 파마슈티칼스 인코포레이티드 개선된 경쟁적 리간드 결합 검정
CA3150234C (en) 2019-09-24 2023-12-12 Robert Stairs Systems and methods for chromatography use and regeneration
US11560595B2 (en) 2019-10-03 2023-01-24 Dasman Diabetes Institute Method for preventing progression to type II Diabetes
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
KR20220092927A (ko) 2019-11-04 2022-07-04 메디뮨 리미티드 신장 장애를 치료하기 위한 항 il-33 치료제
WO2021089563A1 (en) 2019-11-04 2021-05-14 Medimmune Limited Methods of using il-33 antagonists
CN114760986A (zh) 2019-11-25 2022-07-15 里珍纳龙药品有限公司 使用非水性乳液的持续释放调配物
KR20220119446A (ko) * 2019-12-23 2022-08-29 사노피 바이오테크놀로지 Il-33 길항제 및/또는 il-4r 길항제를 투여하여 알레르기성 천식을 치료 또는 예방하는 방법
CN113214395A (zh) * 2020-01-21 2021-08-06 迈威(上海)生物科技股份有限公司 抗st2抗体及其应用
WO2021150558A1 (en) 2020-01-21 2021-07-29 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
WO2021180858A1 (en) 2020-03-13 2021-09-16 Medimmune Limited Therapeutic methods for the treatment of subjects with risk alelles in il33
AU2021236306A1 (en) * 2020-03-13 2022-09-15 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
BR112022019937A2 (pt) 2020-04-06 2022-12-13 Medimmune Ltd Tratamento de síndrome do desconforto respiratório agudo com antagonistas de ligação de eixo de il-33
EP4136254A4 (en) * 2020-04-13 2024-05-22 Maddon Advisors LLC COMPOSITIONS TARGETING ACE2 AND METHODS OF TREATING COVID-19
BR112022022620A2 (pt) 2020-05-11 2022-12-20 Medimmune Ltd Formulações de anticorpos anti-il-33
AU2021271960A1 (en) * 2020-05-12 2023-02-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ST2 antigen binding protein
KR102789102B1 (ko) * 2020-08-18 2025-03-28 성균관대학교산학협력단 Il-33 항체 또는 이의 항원 결합 단편
CN116209772A (zh) 2020-08-31 2023-06-02 瑞泽恩制药公司 用于提高细胞培养性能和减少天冬酰胺序列变体的天冬酰胺补料策略
CN114249825A (zh) * 2020-09-25 2022-03-29 三生国健药业（上海）股份有限公司 结合人il-33的抗体、其制备方法和用途
WO2022115588A1 (en) 2020-11-25 2022-06-02 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
CA3205135A1 (en) 2020-12-17 2022-06-23 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
CN116761880A (zh) 2021-01-20 2023-09-15 瑞泽恩制药公司 改进细胞培养物中的蛋白质滴度的方法
CA3207883A1 (en) 2021-03-03 2022-09-09 Xiaobin Xu Systems and methods for quantifying and modifying protein viscosity
KR20230162932A (ko) 2021-03-26 2023-11-29 리제너론 파아마슈티컬스, 인크. 혼합 프로토콜 개발을 위한 방법 및 시스템
TW202314240A (zh) 2021-06-01 2023-04-01 美商再生元醫藥公司 微晶片毛細管電泳分析及試劑
CN113493513B (zh) * 2021-06-30 2022-07-12 深圳大学 抗人il-33中和性自身抗体及其制备方法和应用
CN113603775B (zh) * 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
EP4405390A1 (en) 2021-09-20 2024-07-31 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
WO2023059800A2 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
AU2022359898A1 (en) 2021-10-07 2024-03-21 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
AU2022376179A1 (en) 2021-10-26 2024-05-16 Regeneron Pharmaceuticals, Inc. Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
JP2024544885A (ja) 2021-11-10 2024-12-05 ジェネンテック， インコーポレイテッド 抗インターロイキン－３３抗体及びその使用
WO2023166420A1 (en) * 2022-03-03 2023-09-07 Pfizer Inc. Multispecific antibodies and uses thereof
TW202346856A (zh) 2022-03-18 2023-12-01 美商里珍納龍藥品有限公司 分析多肽變體的方法及系統
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
TW202423973A (zh) 2022-08-19 2024-06-16 英商梅迪繆思有限公司 選擇患者以用ｉｌ—３３軸拮抗劑進行治療之方法
US20240198253A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2024158880A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
US20240248097A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
WO2024229136A1 (en) 2023-05-01 2024-11-07 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol
KR102773101B1 (ko) 2023-08-28 2025-02-26 서울대학교산학협력단 세포독성능을 갖는 제2형 선천성 림프구 세포, 이의 제조방법 및 용도
JP7668943B2 (ja) * 2023-08-30 2025-04-25 ファイザー・インク 多重特異性抗体およびその使用
US20250086164A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
US20250095773A1 (en) 2023-09-18 2025-03-20 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
WO2025072597A2 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
WO2025096932A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025120567A1 (en) 2023-12-07 2025-06-12 Medimmune Limited Method of treatment of asthma
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US550362A (en) 1895-11-26 crosby
US1000056A (en) 1910-11-03 1911-08-08 Carlos Van Bergh Threshing-machine.
US1001164A (en) 1911-06-09 1911-08-22 Arthur W Porter Cotton-sweep.
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5576191A (en) 1994-06-17 1996-11-19 Immunex Corporation Cytokine that binds ST2
US20070042978A1 (en) 2002-12-19 2007-02-22 Jean-Philippe Girard Nf-hev compositions and methods of use
NZ549040A (en) * 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
US7666622B2 (en) 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
WO2007140205A2 (en) 2006-05-24 2007-12-06 Biogen Idec Ma Inc. Methods of treating fibrosis
CN101454345B (zh) 2006-06-02 2012-08-08 瑞泽恩制药公司 人il-6受体的高亲和力抗体
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
IE20080331A1 (en) 2007-04-26 2009-07-08 Trinity College Dublin Products for altering cytokine activity and methods therefor
CA2686683A1 (en) 2007-05-18 2008-11-27 Medimmune, Llc Il-33 in inflammatory disease
CA2703335A1 (en) 2007-10-26 2009-04-30 Arturo Zychlinsky Inhibitors of caspase i-dependent cytokines in the treatment of neurodegenerative disorders
WO2011031600A1 (en) 2009-09-10 2011-03-17 Schering Corporation Use of il-33 antagonists to treat fibrotic disease
US9090694B2 (en) 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
JP6404314B2 (ja) 2013-03-15 2018-10-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−３３拮抗薬とその使用法
WO2015099175A1 (ja) 2013-12-26 2015-07-02 田辺三菱製薬株式会社 ヒト抗ｉｌ－３３中和モノクローナル抗体
ES2866935T3 (es) 2014-01-10 2021-10-20 Anaptysbio Inc Anticuerpos dirigidos contra interleucina-33 (IL-33)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11738081B2 (en) 2015-03-31 2023-08-29 Medimmune Limited Polynucleotides encoding IL33 antibodies and methods of using the same

Also Published As

Publication number Publication date
EP3683235A1 (en) 2020-07-22
HUE067119T2 (hu) 2024-10-28
PL3683235T3 (pl) 2024-08-05
JP2016513644A (ja) 2016-05-16
MX377712B (es) 2025-03-11
JP6845876B2 (ja) 2021-03-24
TWI633119B (zh) 2018-08-21
MY174740A (en) 2020-05-13
AU2014248839A1 (en) 2015-08-20
EP2970460B1 (en) 2020-04-29
HRP20200846T1 (hr) 2020-08-21
JP6479755B2 (ja) 2019-03-06
SG11201505745WA (en) 2015-08-28
NZ710831A (en) 2021-04-30
ZA201505376B (en) 2016-07-27
IL261743A (en) 2018-10-31
US10519230B2 (en) 2019-12-31
MX2020012416A (es) 2021-02-09
JP2019088311A (ja) 2019-06-13
UY35417A (es) 2014-10-31
CA2902172A1 (en) 2014-10-09
US20240425580A1 (en) 2024-12-26
US12037388B2 (en) 2024-07-16
AU2014248839B2 (en) 2019-01-03
EP4403570A2 (en) 2024-07-24
US20140271658A1 (en) 2014-09-18
PH12015501656B1 (en) 2015-10-19
CA2902172C (en) 2024-04-02
US20180251542A1 (en) 2018-09-06
CN105051063B (zh) 2019-08-16
US10000564B2 (en) 2018-06-19
JO3532B1 (ar) 2020-07-05
WO2014164959A2 (en) 2014-10-09
EA031745B1 (ru) 2019-02-28
HRP20240774T1 (hr) 2024-09-13
EP2970460A2 (en) 2016-01-20
US20200071396A1 (en) 2020-03-05
TW201522370A (zh) 2015-06-16
ES2804592T3 (es) 2021-02-08
CN105051063A (zh) 2015-11-11
BR112015020470A2 (pt) 2017-10-10
RS65586B1 (sr) 2024-06-28
US11104729B2 (en) 2021-08-31
MX2015010599A (es) 2015-12-15
DK2970460T3 (da) 2020-06-02
KR20150126598A (ko) 2015-11-12
PH12015501656A1 (en) 2015-10-19
US20210363236A1 (en) 2021-11-25
KR102103159B1 (ko) 2020-05-29
PL2970460T3 (pl) 2020-10-05
EP4403570A3 (en) 2024-10-02
SI3683235T1 (sl) 2024-07-31
LT2970460T (lt) 2020-06-10
PT3683235T (pt) 2024-06-24
LT3683235T (lt) 2024-06-25
WO2014164959A3 (en) 2015-02-19
EA201591716A1 (ru) 2016-07-29
RS60503B1 (sr) 2020-08-31
EP3683235B1 (en) 2024-05-22
DK3683235T3 (da) 2024-07-08
US20160362487A1 (en) 2016-12-15
HK1220467A1 (en) 2017-05-05
CL2018000101A1 (es) 2018-07-06
US9453072B2 (en) 2016-09-27
PT2970460T (pt) 2020-06-02
IL261743B (en) 2020-11-30
HUE051018T2 (hu) 2021-01-28
IL240354A0 (en) 2015-09-24
FI3683235T3 (fi) 2024-07-02
SI2970460T1 (sl) 2020-07-31
ES2983609T3 (es) 2024-10-23

Similar Documents

Publication Publication Date Title
CL2015002469A1 (es) Anticuerpos dirigidos contra il-33 y sus usos
CL2024003234A1 (es) Polipéptidos modificados y usos de los mismos.
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
CL2017000651A1 (es) Anticuerpos anti-glucagón y sus usos
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
MX2015011408A (es) Antagonistas de il-33 y usos de estos.
BR112019006865A2 (pt) caspases induzíveis e métodos para uso
MX373280B (es) Anticuerpos anti-egfrviii y usos de los mismos.
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
MX2016005631A (es) Anticuerpos anti-alfa-sinucleina y metodos de uso.
MX380146B (es) Inhibidores mk2 y usos de los mismos.
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
CL2018001108A1 (es) Composiciones y métodos para transducción de tumores
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
BR112017004444A2 (pt) novos anticorpos anti-mfi2 e métodos de uso
MX2022007816A (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de higado graso, y uso de los mismos.
CL2018000621A1 (es) Ciano tienotriazolpirazinas y usos de las mismas solicitudes relacionadas.
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
CL2017001135A1 (es) Anticuerpos mejorados contra il-6
PE20151925A1 (es) Anticuerpos anti-igf-1r con abolicion de la union al fcrn y su utilizacion en el tratamiento de enfermedades oculares vasculares
PE20170192A1 (es) Mutagenesis dirigida al sitio de anticuerpos receptor desencadenante expresado en las meloid tipo 1 (trem-1) para reducir la viscosidad
UY36961A (es) Receptores celulares universales programables y métodos para usar los mismos
PE20220297A1 (es) Neutralizacion del virus chikungunya mediada por anticuerpos